EGFR and cancer: Convergence of the mutp53-HSF1 liaison on the Her2/EGFR pathways provides a strong rationale to test the targeted therapies that are currently on the market (e.g., Her2-targeted trastuzamab, pertuzumab, T-DM1, and lapatinib) specifically in mutp53-harboring cancers.